PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 281 filers reported holding PACIRA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 6.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $29,713,120 | -18.2% | 968,485 | +6.8% | 1.89% | -8.5% |
| Q2 2023 | $36,335,671 | +19.7% | 906,805 | +21.9% | 2.06% | +19.6% |
| Q1 2023 | $30,346,153 | +79.7% | 743,596 | +70.0% | 1.72% | +78.1% |
| Q4 2022 | $16,883,574 | -22.2% | 437,285 | +7.2% | 0.97% | -23.1% |
| Q3 2022 | $21,695,000 | -12.3% | 407,878 | -3.8% | 1.26% | +5.3% |
| Q2 2022 | $24,724,000 | -29.1% | 424,080 | -7.2% | 1.20% | -14.0% |
| Q1 2022 | $34,863,000 | +37.9% | 456,798 | +8.7% | 1.39% | +54.7% |
| Q4 2021 | $25,284,000 | +35.2% | 420,205 | +25.8% | 0.90% | +30.0% |
| Q3 2021 | $18,701,000 | -6.7% | 333,949 | +1.0% | 0.69% | -3.1% |
| Q2 2021 | $20,054,000 | -47.9% | 330,483 | -39.9% | 0.71% | -43.2% |
| Q1 2021 | $38,521,000 | +16.2% | 549,596 | -0.8% | 1.26% | +7.7% |
| Q4 2020 | $33,147,000 | -3.8% | 553,934 | -3.4% | 1.17% | -16.1% |
| Q3 2020 | $34,473,000 | +7.1% | 573,408 | -6.6% | 1.39% | +0.5% |
| Q2 2020 | $32,196,000 | +53.0% | 613,615 | -2.2% | 1.38% | +17.5% |
| Q1 2020 | $21,047,000 | +11.5% | 627,714 | +50.6% | 1.18% | +84.0% |
| Q4 2019 | $18,883,000 | +15.8% | 416,851 | -2.7% | 0.64% | +9.6% |
| Q3 2019 | $16,311,000 | -14.1% | 428,460 | -1.8% | 0.58% | -7.6% |
| Q2 2019 | $18,985,000 | +7.5% | 436,527 | -5.9% | 0.63% | +10.9% |
| Q1 2019 | $17,661,000 | -9.1% | 464,040 | +2.7% | 0.57% | -19.7% |
| Q4 2018 | $19,438,000 | +20.1% | 451,827 | +37.2% | 0.71% | +22.5% |
| Q3 2018 | $16,183,000 | +49.4% | 329,258 | -2.6% | 0.58% | +47.0% |
| Q2 2018 | $10,834,000 | +6.7% | 338,032 | +3.7% | 0.39% | -0.5% |
| Q1 2018 | $10,151,000 | -31.3% | 325,871 | +0.6% | 0.40% | -31.8% |
| Q4 2017 | $14,780,000 | +44.0% | 323,769 | +18.4% | 0.58% | +28.0% |
| Q3 2017 | $10,267,000 | +11.2% | 273,434 | +41.2% | 0.45% | +12.9% |
| Q2 2017 | $9,236,000 | +59.2% | 193,637 | +52.2% | 0.40% | +42.0% |
| Q1 2017 | $5,800,000 | +46.1% | 127,193 | +3.5% | 0.28% | +41.5% |
| Q4 2016 | $3,970,000 | +13.1% | 122,895 | +19.8% | 0.20% | +8.7% |
| Q3 2016 | $3,511,000 | +41.2% | 102,605 | +39.2% | 0.18% | +28.7% |
| Q2 2016 | $2,486,000 | -34.4% | 73,701 | +3.0% | 0.14% | -34.7% |
| Q1 2016 | $3,791,000 | -29.4% | 71,558 | +2.4% | 0.22% | -28.7% |
| Q4 2015 | $5,366,000 | +224.0% | 69,884 | +73.5% | 0.31% | +186.9% |
| Q3 2015 | $1,656,000 | -36.6% | 40,282 | +9.0% | 0.11% | -29.1% |
| Q2 2015 | $2,614,000 | – | 36,956 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |